Restraining order for dendritic cells: all quiet on the fetal front

Rana Chakraborty¹ and Bali Pulendran²

¹Division of Pediatric Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
²Emory Vaccine Center at Yerkes National Primate Research Center, Atlanta, Georgia, USA.

The paradoxical ability to launch effective immunity against pathogens while avoiding the horror autotoxicus of autoimmunity is one of the most remarkable features of the mammalian immune system. This assumes a particular evolutionary significance at the maternal/fetal interface, where avoidance of immune reactivity to the fetus is vital to the propagation of the species itself. Several mechanisms of suppressing maternal immunity against the fetus have been described. The article by Collins et al. in this issue of the JCI describes a novel mechanism of avoiding immune surveillance in which the migratory capacity of dendritic cells at the maternal/fetal interface is restrained (see the related article beginning on page 2062).

In eutharian mammals, the implantation of an embryo in a mother’s uterus creates an incongruous immunological paradox. The hemochorial placenta provides optimal nourishment and protection to the embryo; however, persistent and intimate contact between the uterine lining (decidua) and the semi-allogeneic fetus (sharing some but not all genes of the mother) should evoke significant immunologic responses akin to a mismatched organ transplant. During pregnancy, however, a seemingly harmonious temporary coexistence of two immunologically distinct multicellular organisms occurs so that the fetus remains protected from any maternal immune responses. Understanding this evolutionary adaptation of immune evasion in the placenta will be pivotal to understanding the induction and maintenance of tolerance from conception to senescence and may provide useful insights into the immunologic role of the placenta during prematurity and recurrent abortions, and during acute and chronic maternal viral infections.

Medawar’s postulates

In 1953 Sir Peter Medawar proposed three general mechanisms of immune evasion within the uterus, which when gravid constitutes an immune-privileged site (1). First, there could be induction of immunological tolerance of the mother for fetal antigens. Second, an anatomical and physiological barrier between mother and fetus might prevent access of maternal immune cells to fetal antigens, a mechanism similar to that in effect in other immune-privileged sites, including the testes, eyes, and brain. Third, fetal cells might suppress the expression of alloantigens. These postulates remain plausible but do not explain the paradox of how the maternal immune system acquires unresponsiveness to fetal antigens, while maintaining immune reactivity against infections. A corollary to Medawar’s postulates has been put forward to explain this paradox: one that involves site-specific suppression of maternal immune responses at the maternal/fetal interface, thus controlling immune reactivity to the fetus without compromising immunity to pathogens elsewhere (2). The mechanisms underlying site-specific immune suppression facilitating fetal engraftment have been the subject of intense research, and several have been proposed. These include: (i) the expression of FasL by the fetus, which induces Fas-mediated deletion of maternal T cells reactive to the fetus; (ii) expression of nonclassical HLA-G major histocompatibility molecules in cytotrophoblast cells at the maternal/fetal interface, where they maintain a tolerogenic status between the mother and fetus; and (iii) the presence of cells expressing immunosuppressive molecules such as indoleamine 2,3-dioxygenase (IDO), IL-10, TGF-β, and PGE₂ (3–5). In addition, CD4⁺Foxp3⁺ Tregs, which suppress the activation of the immune system, have been documented to increase in number during early human pregnancy (6).

Maternal/fetal détente

The study by Collins et al., reported in this issue of the JCI, presents new insights into the role of DCs in mediating this site-specific suppression (7). DCs represent a rare population of APCs that have long been known to play a key role in sensing pathogens as well as initiating and tuning the quality of the subsequent immune response (8). Like lymphocytes, DCs also comprise distinct cell subsets, which are functionally specialized to produce distinct cytokines that differentially regulate the type of immune response induced. Immature DCs are scattered at the portals of pathogen entry, such as at the mucosal surfaces of the intestine, lungs, and reproductive tracts, and are equipped to sense conserved molecular patterns of pathogens through receptors such as TLRs (9, 10). Upon sensing a pathogen, immature DCs rapidly migrate to the draining LNs and stimulate the naïve antigen-specific T cells, thus launching an immune response. Recent work demonstrates that DCs can also suppress the immune response, through the generation of Tregs, and DCs exhibiting this immune-suppressive property have been observed at mucosal sites such as the gut, lung, and decidua (9, 10).

The study by Collins et al. (7) examines the effect of decidualization (encasement of the fetus and placenta in a stromal cell–derived structure called the decidua) on decidual DC migration and function in a murine model of pregnancy (Figure 1). The authors first used flow cytometry to characterize populations of cellular subsets expressing MHC class II (MHCII) in the uterine tissues of virgin mice that had been treated with a high-dose regimen of progesterone designed to simu-
late pregnancy and suppress the variation in leukocyte numbers that occurs during the estrous cycle. Putative populations of DCs were defined as cells expressing high levels of MHCII and CD11c (an integrin molecule commonly found on murine DCs) and not expressing F4/80 (a molecule commonly found on macrophages). These MHCII+CD11c^hi F4/80^− cells could further be subdivided into CD11b^lo CD103^+ and CD11b^hi CD103^− cells (Figure 1), similar to the subsets that have been reported at other mucosal surfaces (10).

To assess whether such DCs could migrate to the draining uterine LNs in WT mice, the authors labeled such DCs in situ by injecting CFSE into the lumen via a nontraumatic transcervical approach and observed the appearance of an MHCII+CD11c^hi CD11b^lo CD103^+ CD11b^hi CD103^− population within uterine LNs 28 hours later (7). This population could also be subdivided into CD11b^lo CD11c^hi CD103^+ and CD11b^hi CD103^− cells (Figure 1). Furthermore, i.v. injection of a TLR agonist, LPS, a potent stimulus for DC migration and maturation, resulted in enhanced DC migration to the LNs. In contrast to these results in WT mice, DCs in mice lacking the chemokine receptor for CCL21 (CCR7, which is known to guide the migration of DCs from peripheral tissues to the T cell–rich areas of the draining LNs) did not appear to migrate to the uterine LNs, either in the steady state or even in response to LPS. These experiments provide evidence of decidual DC entrapment and suggest that a structurally intact decidua appeared to impede the chemokine-directed migration of DCs to the lymphatic vessels of the uterus. This DC entrapment could be the method by which an anti-fetal/placental T cell response is prevented, thus fostering immunological acceptance of the fetus by the maternal immune system.

DCs on a treadmill
To understand the apparent lack of involvement of decidual DCs in mediating the anti-fetal/placental T cell response, the authors evaluated the prevalence and location of these cells in the pregnant uterus (7). With uterine growth, DCs in the myometrium increased in density. However, surprisingly, from E4.5 to E12.5 during pregnancy there was an approximately
6-fold reduction in the density of DCs in the decidua (Figure 1). Interestingly, WT and Cer7+/− mice showed similar densities of DCs in both the decidua and myometrium, suggesting that CCR7-dependent cell migration was likely not a key determinant in regulating the densities of DCs at these sites. Previous work has shown that lymphatic vessels positive for lymphatic vessel endothelial receptor-1 (LYVE-1, a type 1 integral membrane glycoprotein expressed on the endothelial cells lining lymphatic vessels) are localized in the myometrium, far away from the maternal/fetal interface, upon embryo implantation (12). In the present study, the authors demonstrate that the myometrial lymphatic structures were the only structures to express the chemokine CCL21 (also known as 6Ckine or SLC), which is a ligand for CCR7 and drives entry into the lymphatic vessels. This raised the possibility that DCs at the maternal/fetal interface would first migrate to the myometrium in order to reach the draining LNs. The authors tested this idea directly by transcervical injection of CFSE as outlined above; however, to ensure that access of CFSE to the decidual tissues was unobstructed by the implanted embryo, the authors used a well-established technique to generate pseudopregnant mice (4) containing artificial decidua. Surprisingly, only a small proportion of DCs in the uterine LNs were CFSE+ 24 hours after CFSE injection, and even those few cells were CFSEdim, suggesting that decidual DCs failed to migrate to the LNs. In contrast, myometrial DCs seemed competent to migrate to the draining LNs. Curiously, decidual DCs retained maturation status in situ and migratory capacity toward CCL21 ex vivo when purified cells were subject to Transwell chemotaxis assays, suggesting that there was no intrinsic migratory defect in the decidual DCs. However, these cells remained nonpermissive for cell migration in vivo and in explants even after LPS stimulation and culture in medium containing CCL21. These experiments provide evidence of decidual DC entrapment and also suggest that a structurally intact decidua appeared to impede the chemokine-directed migration of DCs to the lymphatic vessels of the uterus (Figure 1).

Placental particularities
The findings reported by Collins et al. (7) suggest that this DC entrapment could be a mechanism by which an anti-fetal/placental T cell response is prevented and thus fosters immunological acceptance of the fetus by the maternal immune system. These provocative observations raise questions about the mechanisms underlying DC entrapment and their consequences. First, although reduced decidual DC migration is demonstrated, the authors do not address how this could lead to T cell tolerance (7). Clearly, soluble antigen drains to the LNs via passive antigen transport and can thus be presented to LN-resident DCs. Are these uterine LN DCs tolerogenic? The ability of such LN DCs versus DCs at the maternal/fetal interface to induce T cell tolerance or Tregs in vitro should be investigated in future studies. Second, by what mechanism does the formation of the decidua restrain DC migration? Is it simply a physical barrier, or is the CCR7-dependent chemokine gradient disrupted, perhaps as a result of local production of other regulatory factors within the decidual environment? In this context, the mechanisms controlling the emigration of epidermal Langerhans cells (LCs) after activation include the antiinflammatory cytokines IL-1Ra (13), IL-4 (14), and IL-10 (15), which have been shown to act as negative regulators of migration. Third, are the DCs in the decidua derived from the mother or the fetus? If the latter, are these DCs very immature and therefore functionally incapable of stimulating T cells, even under strong maturation stimuli? Fourth, if decidual DCs do not migrate to LNs, what is their physiological function? Do they mediate innate responses against infections at the site? In this context, HIV-1, HBV, HCV, herpes, and other viruses have very low rates of transplacental transmission, suggesting that the maternal/fetal interface may nonspecifically restrict viral entry and/or replication (4). Might this be mediated by the innate functions of decidual DCs? Alternatively, by entrapment of decidual DCs, antigen presentation and local viral dissemination may be restricted, which would thereby account for the lack of fetal infection.

These results are reminiscent of an earlier study that showed that the helminth Schistosoma mansoni impairs the migration of LCs from the epididymis to the LNs (16). The inhibitory effect was mediated by parasite-derived PGD2, which specifically impeded the TNF-α-triggered migration of LCs through the adenylylcyclase-coupled PGD2 receptor (DP receptor). This raises the question of whether a similar mechanism involving prostaglandins or other antiinflammatory mediators is responsible for the observed DC entrapment in the decidua. In this context, it is now well appreciated that during normal pregnancy, tolerogenic stimuli from trophoblasts such as progesterone, PGE2, IDO, and vitamin D result in an alternative activation of resident DCs, which results in the establishment of immune tolerance at the maternal/fetal interface (17–19).

In summary, the Collins et al. study (7) highlights an unappreciated mechanism by which the murine decidua inhibits immune surveillance of the maternal/fetal interface. Clinical implications in humans include the potential relevance for immunologic tolerance in mothers with recurrent abortions or premature deliveries. Thus, if the progressive loss of decidual DC tissue density over the first half of postimplantation development and DC entrapment within the decidua represent a normal physiologic state, then migration of human decidual DCs outside the uterus may result in prematurity and recurrent abortions. With further understanding of this process, it may be possible to devise strategies to regulate decidual immunity therapeutically in women with recurrences of these adverse outcomes during pregnancy. Furthermore, such DCs may mediate innate control of viruses such as HIV-1 that have very low rates of transplacental transmission. Future studies examining decidual DCs in humans will surely provide further deep insights into the evolutionary adaptations of the maternal/fetal microcosm that are vital to the survival of so many species. As Medawar might have exclaimed, "Fascinating, in every particular!"

Acknowledgments
The work in the authors’ laboratory was supported by funding from the NIH (grants R01 DK057665, R01 AI048638, U19 AI057266, U54 AI057157, N01 AI50019, and N01 AI50025) and from the Bill and Melinda Gates Foundation to B. Pulendran.

Address correspondence to: Bali Pulendran, Emory Vaccine Center at Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, Georgia 30329, USA. Phone: (404) 727-8945; Fax: (404) 727-8199; E-mail: bпulend@emory.edu.


